KRAS and pancreatic ductal adenocarcinoma: For example, activating mutations in KRAS are the most frequent alterations in pancreatic ductal adenocarcinomas (PDAC), yet inducing a Kras mutation in the epithelial cells of the pancreas of mice is insufficient to drive robust tumorigenesis.